



- (51) **International Patent Classification:**
A61K 39/00 (2006.01) A61K 39/395 (2006.01)
- (21) **International Application Number:**
PCT/US2021/043868
- (22) **International Filing Date:**
30 July 2021 (30.07.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/059,497 31 July 2020 (31.07.2020) US
- (71) **Applicant:** R.P. SCHERER TECHNOLOGIES, LLC
[US/US]; 112 North Curry Street, Carson City, Nevada 89703 (US).
- (72) **Inventors:** RABUKA, David; 202 Stanford Avenue, Kensington, California 94708 (US). DRAKE, Penelope M.; 3663 Swallow Court, Castro Valley, California 94546 (US). KIM, Yun Cheol; 587 Cabot Road, Walnut Creek, California 94598 (US). BARFIELD, Robyn M.; 5959 Horton Street, Suite 400, Emeryville, California 94608 (US). BAUZON, Maxine; 1033 Park Street, Hercules, California 94547 (US). OGUNKOYA, Ayodele; 5959 Horton Street, Emeryville, California 94608 (US).
- (74) **Agent:** NG, Rudy; Bozicevic, Field & Francis LLP, 201 Redwood Shores Pkwy, Suite 200, Redwood City, California docket@bozpat.com (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,


(54) **Title:** ANTIBODY SPECIFIC FOR MUCIN-1 AND METHODS OF USE THEREOF

FIG. 2A

(57) **Abstract:** The present disclosure provides antibodies specific for Mucin 1. Nucleic acids that encode one or both of the variable chains of an antibody of the present disclosure are also provided, as are cells that include such nucleic acids. Also provided are compositions that include the antibodies of the present disclosure, including in some instances, pharmaceutical compositions. Methods of making and using the antibodies of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual having a cell proliferative disorder a therapeutically effective amount of an antibody of the present disclosure, where the antibody is administered to the individual to enhance an immune response, e.g., a T cell response, to abnormally proliferating cells of the cell proliferative disorder. The antibodies are also useful in various diagnostic, and monitoring applications, which are also provided.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*